GLOW

Overview

GLOW Blend is a fixed-ratio co-formulation of three peptides selected for their non-overlapping but complementary roles in tissue-repair signaling. The 50 mg / 10 mg / 10 mg ratio (GHK-Cu : BPC-157 : TB-500) reflects the copper-tripeptide-dominant stack widely adopted across research peptide suppliers.[1][2]

The rationale for combining these peptides is mechanistic: each component engages a distinct molecular target. GHK-Cu functions as a copper delivery vehicle and a master gene modulator, with reported >50% expression changes across approximately 31% of human genes.[9] BPC-157 activates the VEGFR2-Akt-eNOS cascade, driving angiogenesis and nitric-oxide-mediated repair.[5] TB-500 binds monomeric G-actin in a 1:1 stoichiometric complex via its LKKTETQ motif, enabling cytoskeletal reorganization required for cell migration.[6]

Each component peptide has been individually evaluated in dozens of preclinical wound-healing, angiogenesis, and connective-tissue models. There are no published peer-reviewed studies of the three-peptide blend itself; investigators using the combined formulation infer additive activity from the individual literature. Researchers should refer to the individual product entries for full mechanism, applications, and citations.

Mechanism of Action — Three-Component Series

1. GHK-Cu (50 mg, 71.4% of mass) — Copper Delivery & Gene Modulation

The largest component, GHK-Cu, is the endogenous tripeptide Gly-His-Lys chelated to a Cu(II) ion. It "redox silences" copper to prevent Fenton-reaction toxicity while delivering Cu into cells for use by lysyl oxidase (collagen crosslinking) and Cu/Zn-SOD. Connectivity Map analysis confirmed GHK modulates >4,000 genes, suppressing inflammatory/metastatic signatures and activating repair programs.[9][10] Stimulates collagen I/III, elastin, GAGs, and decorin synthesis with biphasic dose-response peaking near 10⁻⁹ M.[11]

2. BPC-157 (10 mg, 14.3% of mass) — VEGFR2-Akt-eNOS Angiogenic Cascade

BPC-157 binds and internalizes VEGFR2 on endothelial cells, triggering Akt phosphorylation and eNOS activation, yielding nitric oxide production essential for vascular repair (129–152% increased angiogenesis in chick chorioallantoic membrane and rat hind-limb ischemia models).[5] BPC-157 also activates the FAK-paxillin pathway and upregulates growth-hormone-receptor expression on tendon fibroblasts.[13]

3. TB-500 (10 mg, 14.3% of mass) — G-Actin Sequestration & Cell Migration

The LKKTETQ motif binds monomeric G-actin in a 1:1 complex, regulating polymerization into filamentous actin and enabling cytoskeletal reorganization required for cell motility.[6] TB-500 also engages F1-F0 ATP synthase on endothelial cells (K_D ≈ 12 nM), forms a complex with integrin-linked kinase (ILK) and PINCH that activates Akt2, and upregulates MMP-2/MMP-9 to facilitate basement-membrane remodeling during angiogenesis.[14][15] Note: TB-500 lacks the N-terminal Ac-SDKP tetrapeptide of full-length Tβ4 and therefore does not contribute the anti-fibrotic TGF-β-modulating activity of the parent molecule.[16]

Combined Mechanistic Rationale

No published peer-reviewed pharmacokinetic or pharmacodynamic studies have evaluated the 50/10/10 blend as a single co-administered formulation. All mechanistic content is extrapolated from individual-component literature.

Research Applications

Laboratory studies using the GLOW combination — or the individual components in parallel — have explored:

1. Dermal Wound Healing & Re-Epithelialization — GHK-Cu (collagen/elastin synthesis), BPC-157 (granulation tissue formation), and TB-500/Tβ4 (keratinocyte migration) each independently accelerate full-thickness wound closure in rodent models.[11][17][18]
2. Tendon, Ligament & Skeletal Muscle Repair — BPC-157 has been shown to accelerate Achilles transection healing; TB-500 supports myoblast and tenocyte migration; GHK-Cu modulates MMP/TIMP balance for connective-tissue remodeling.[19][20]
3. Angiogenesis Models — BPC-157 (VEGFR2-driven) and TB-500/Tβ4 (epicardial progenitor mobilization) have both been documented to enlarge collateral vessel networks in ischemia paradigms.[5][21]
4. Dermatology & Hair Follicle Research — GHK-Cu enlarges follicle size and prolongs anagen phase in preclinical models; the actin-binding region of Tβ4 (the TB-500 fragment) has been identified as an active site for hair-growth signaling.[22][23]
5. Anti-Inflammatory & Antioxidant Models — All three components suppress NF-κB activation; GHK-Cu and TB-500 upregulate SOD/catalase; BPC-157 and TB-500 attenuate liver fibrosis in CCl₄/ethanol models.[24][25]
6. Corneal & Ocular Surface Repair — BPC-157 and the Tβ4-derived peptides have independently demonstrated accelerated corneal epithelial repair in preclinical studies.[26]

Important: every cited study above used individual peptides, not the GLOW combination. Researchers using the blend should design experiments accordingly and not assume that the sum of single-agent effects has been validated in combination.

Preclinical Research Summary (Component-Level)

No peer-reviewed studies have evaluated the GLOW 50/10/10 blend as a co-administered formulation. The studies below summarize key findings for each individual component. For full per-component data tables and clinical references, see the dedicated GHK-Cu, BPC-157, and TB-500 entries.

Component-Level Highlights